Literature DB >> 11694644

Biopharmacologic and herbal therapies for cancer: research update from NCCAM.

M A Richardson1.   

Abstract

During the past decade, use of complementary and alternative medicine (CAM) by the American public increased from 34% in 1990 to 42% in 1995 with related out-of-pocket expenditures estimated at $27 billion. Among cancer patients, use of CAM ranges between 30 and 75% worldwide and includes dietary approaches, herbals and other biologically based treatments such as melatonin, mushrooms, shark cartilage and high dose vitamins and minerals. Concerns about herb-nutrient-drug interactions and product quality and standardization emphasize the need for rigorous research. In 1998, Congress mandated the creation of the National Center for Complementary and Alternative Medicine (NCCAM) to conduct and support such research of CAM therapies. The NCCAM portfolio for oncology is rapidly growing. As of July 2001, 26 projects are underway, two specialized centers are funded for cancer research and four botanical centers are cofunded with the Office of Dietary Supplements. Investigations are targeting herbals and complex herbal formulas; single dietary supplements and complex dietary regimens; biological agents; and mind-body, body-based and frontier approaches. Of these, biopharmacologic and herbal therapies are a major focus of research. The NCCAM portfolio illustrates how research of CAM, particularly studies of biopharmacologic and herbal approaches for cancer, is developing systematically and rigorously.

Entities:  

Mesh:

Year:  2001        PMID: 11694644     DOI: 10.1093/jn/131.11.3037S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  9 in total

Review 1.  Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review.

Authors:  Esther L Davis; Byeongsang Oh; Phyllis N Butow; Barbara A Mullan; Stephen Clarke
Journal:  Oncologist       Date:  2012-08-29

2.  Medicinal mushroom Phellinus linteus as an alternative cancer therapy.

Authors:  Daniel Sliva
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

3.  Chemotherapeutic Vulnerability of Triple-negative Breast Cancer Cell-derived Tumors to Pretreatment with Vernonia amygdalina Aqueous Extracts.

Authors:  Carolyn B Howard; Roderick McDowell; Kidus Feleke; Evangeline Deer; Symone Stamps; Easter Thames; Vikash Singh; Shehla Pervin
Journal:  Anticancer Res       Date:  2016-08       Impact factor: 2.480

4.  V. Amygdalina: Folk Medicine, Analysis, and Potential Application for Cancer Treatment.

Authors:  Ernest B Izevbigie; C B Howard; K S Lee
Journal:  Curr Pharm Anal       Date:  2008       Impact factor: 0.890

Review 5.  Complications of traditional Chinese/herbal medicines (TCM)--a guide for perplexed oncologists and other cancer caregivers.

Authors:  Joanne Chiu; Thomas Yau; Richard J Epstein
Journal:  Support Care Cancer       Date:  2008-11-14       Impact factor: 3.603

6.  Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells.

Authors:  Dan Wang; Bijaya Upadhyaya; Yi Liu; David Knudsen; Moul Dey
Journal:  BMC Cancer       Date:  2014-08-15       Impact factor: 4.430

7.  Use of complementary/alternative therapies by women with advanced-stage breast cancer.

Authors:  Joannie Shen; Ronald Andersen; Paul S Albert; Neil Wenger; John Glaspy; Melissa Cole; Paul Shekelle
Journal:  BMC Complement Altern Med       Date:  2002-08-13       Impact factor: 3.659

8.  Recent perspectives on the anticancer properties of aqueous extracts of Nigerian Vernonia amygdalina.

Authors:  Carolyn Bingham Howard; William K Johnson; Shehla Pervin; Ernest B Izevbigie
Journal:  Botanics       Date:  2015-11-30

9.  Antiproliferative Effects of Pancratium Maritimum Extracts on Normal and Cancerous Cells.

Authors:  Ghaleb Tayoub; Mohmad Al-Odat; Amal Amer; Abdulmunim Aljapawe; Adnan Ekhtiar
Journal:  Iran J Med Sci       Date:  2018-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.